MARKET

SGP

SGP

SpyGlass Pharma, Inc.
NASDAQ
22.61
-2.59
-10.28%
After Hours: 23.06 +0.45 +1.99% 16:19 03/27 EDT
OPEN
24.63
PREV CLOSE
25.20
HIGH
24.63
LOW
21.29
VOLUME
95.37K
TURNOVER
--
52 WEEK HIGH
32.44
52 WEEK LOW
20.16
MARKET CAP
755.77M
P/E (TTM)
-8.4965
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on NA Companies: BitGo Holdings, Inc. Class A (BTGO) and SpyGlass Pharma (Nasdaq: SGP)
TipRanks · 1d ago
Spyglass Pharma FY2025 net loss widens 37% to $(40) million; general and administrative expense jumps 73% to $12 million
Reuters · 1d ago
SpyGlass Pharma, Inc. GAAP EPS of -$5.72
Seeking Alpha · 1d ago
SpyGlass Pharma Q4 EPS $(5.72) Down From $(4.58) YoY
Benzinga · 1d ago
*SpyGlass Pharma 4Q Loss/Shr $5.72 >SGP
Dow Jones · 1d ago
SPYGLASS PHARMA INC: Q4 NET LOSS $5.72 PER BASIC AND DILUTED SHARE
Reuters · 1d ago
SpyGlass Pharma FY2025 net loss widened 36.64% to $39.9 million; loss per share widened to $17.98
Reuters · 1d ago
*SpyGlass Pharma Cash, Cash Equivalents and Short-Term Investments Expected to Fund Planned Ops Through 2028 >SGP
Dow Jones · 1d ago
More
About SGP
SpyGlass Pharma Inc is a United States-based ophthalmic drug delivery company. The Company is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye.

Webull offers SpyGlass Pharma, Inc. stock information, including NASDAQ: SGP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGP stock methods without spending real money on the virtual paper trading platform.